PHILADELPHIA — The American Association for Cancer Research welcomes Patrice J. Morin, Ph.D., as director of scientific review and grants administration. Morin, who has been actively involved in cancer research for more than 20 years, will be guiding the scientific review and administration of Stand Up To Cancer (SU2C) grants as well as other AACR grants.
“I am absolutely delighted that Pat Morin joined us as a member of the AACR senior staff. He is not only an active cancer researcher with enormous expertise in the field, but he also has strong administrative and organizational skills, and an affable personality that will facilitate his work as a team player and consensus builder,” said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. “His superb judgment and dedication are already making a difference in our grants program, and I look forward to seeing his future accomplishments. His work will undoubtedly benefit the AACR’s ever-increasing grants program.”
Morin received his doctorate in molecular biology from Boston University in 1995, and completed his undergraduate studies in biophysics at the University of Quebec, Canada, where he received his bachelor’s and master’s degree. He has had a robust career in research, with more than 80 publication credits to his name, and has been a longtime member of the AACR.
“The AACR has a long history of funding cutting-edge cancer research and it is a great honor for me to join the AACR as director of scientific review and grants administration. I look forward to working with the cancer research community to continue to expand our grants programs and develop new, innovative mechanisms for funding the most impactful research,” Morin said.
Prior to joining the AACR, Morin was a senior investigator in the Intramural Research Program of the National Institute on Aging at the National Institutes of Health (NIH). After joining the NIH in 1998, he developed a research program that was focused on elucidating the mechanisms of ovarian tumorigenesis. His group was one of the first to perform gene expression profiling in ovarian cancer, and in 2000 he first identified claudin proteins as being abnormally expressed in cancer. These findings led to research investigating the possible use of claudins in targeted therapies and in the detection of various cancers.
Before going to the NIH, Morin was affiliated with Johns Hopkins University Medical Center in Baltimore, Md. While there, he co-authored papers along with Drs. Bert Vogelstein and Ken Kinzler. In addition, he held an adjunct faculty position there from 1998 to the present.
Morin is a long-time member of the AACR. Having served as a grant reviewer on numerous study sections for both government and non-government agencies, he is an expert in the scientific peer review process and grants administration. In addition, for a number of years, he was an associate editor of the AACR’s journal, Cancer Research, and has served as a reviewer of more than 250 manuscripts submitted to various scientific journals. He has given many lectures in the field, chaired scientific symposia and is an acknowledged leader in the cancer field.